Vosoritide is a longer-acting C-type natriuretic peptide (CNP) analog that modulates activity of the fibroblast growth factor receptor 3 (FGFR3) by inhibiting a signaling pathway that mediates its effects, thereby stimulating endochondrial growth, resulting in enhanced growth velocity. It is proposed for the treatment of achondroplasia.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Autologous Fat Grafting for Breast Reconstruction After Breast Cancer Surgery
Focus of the Report: Autologous fat grafting (AFG) is used as an adjunct or primary breast reconstruction procedure in women following breast cancer surgery.
Technology Description: AFG is a minimally invasive procedure that utilizes a patient’s own body fat to fill and correct volume …
Tazverik (Tazemetostat) for Epithelioid Sarcoma
Tazverik is an oral methyltransferase inhibitor indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication …
Transcervical Radiofrequency Ablation with the Sonata System for Symptomatic Uterine Fibroids
Focus of the Report: This report focuses on the transcervical radiofrequency ablation (RFA) with the Sonata system for treatment of symptomatic uterine fibroids (UF).
Technology Description: The Sonata system (formerly the VizAblate system) (Gynesonics Inc.) is a minimally invasive, uterin…
Epi proColon (Epigenomics Inc.)
Focus of the Report: This report evaluates the analytical validity, clinical validity, and clinical utility of the Food and Drug Administration–approved Epi proColon blood-based liquid biopsy test, for the detection of methylated Septin 9 (SEPT9) as cell-free circulating DNA, that is intended to screen for colorectal cancer (CRC) in average-ris…
Occipital Nerve Stimulation for Chronic Cluster Headache
Focus of the Report: This report focuses on occipital nerve stimulation (ONS) for treatment of chronic cluster headache (CH) that has failed to respond to available drug treatments.
Technology Description: ONS involves electrical stimulation of the greater and/or lesser occipital nerve…
Myocardial Strain Imaging by Speckle-Tracking Echocardiography for Evaluation of Dilated Cardiomyopathy
Focus of the Report: This report focuses on myocardial strain imaging (MSI) using speckle-tracking echocardiography for diagnosis and prognosis in patients who have dilated cardiomyopathy (DCM).
Technology Description: MSI involves a sophisticated analysis of images from echocardiogr…
Viltepso (Viltolarsen) for Duchenne Muscular Dystrophy
Viltepso (viltolarsen) is an intravenously administered antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Minimally Invasive Sacroiliac Joint Fusion Using Cylindrical Threaded Implants
Focus of the Report: The use of minimally invasive sacroiliac joint (SIJ) fusion with cylindrical threaded implants (CTIs) for the treatment of adults with SIJ dysfunction who have not experienced adequate relief from nonsurgical management (NSM). Evaluation of minimally invasive SIJ fusion using triangular titanium implants (i.e., iFuse Impl…
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophies
Focus of the Report: This report evaluates the use of voretigene neparvovec-rzyl (Luxturna) for the treatment of vision loss due to inherited retinal dystrophies (IRDs) from confirmed biallelic RPE65 mutations.
Technology Description: Voretigene neparvove…